8-K - enGene Holdings Inc. Warrants | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

enGene Holdings Inc. entered into a Sales Agreement with Leerink Partners LLC on March 9, 2026, to sell up to $100 million of common shares via at-the-market offerings and terminated its prior sales agreement with Jefferies LLC effective March 6, 2026, with no shares sold or penalties under the prior agreement.

Key Takeaways

1Entered Sales Agreement with Leerink Partners LLC on March 9, 2026

2Aggregate offering price up to $100,000,000 of common shares

3Commission to Leerink Partners up to 3.0% of gross proceeds

4Terminated Prior Sales Agreement with Jefferies LLC effective March 6, 2026

5No common shares sold under Prior Sales Agreement

6No termination penalties for Prior Sales Agreement

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 9, 2026, enGene Holdings Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with L

Material Agreement

$100.0M

1.02

Termination of a Material Definitive Agreement. On February 27, 2026, the Company delivered written notice to Jefferies LLC that effective as of March 6, 2026,

Material Agreement

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Sales Agreement, dated March 9, 2026, by and between enGene Holdings Inc. and L

Exhibits Only

Transaction Details

Material Agreement

Agreement: Sales Agreement
Parties: enGene Holdings Inc., Leerink Partners LLC

•May sell common shares up to $100,000,000 aggregate offering price
•At-the-market offering pursuant to Form S-3 Registration Statement (File No. 333-293597)
•Commission up to 3.0% of gross proceeds
•Customary indemnification and expense reimbursement
•No obligation to sell or purchase shares
•No sales in Canada

Exhibits (3)

1.1

EX-1.1

5.1

EX-5.1

8-K